BU
ABMD

BBVA USA’s Abiomed Inc ABMD Stock Holding History

BBVA USA’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$403K Sell
1,237
-193
-13% -$65.4K 0.02% 357
2021
Q2 		$446K Buy
+1,430
New +$439K 0.02% 362

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

BBVA USA's ABMD Position: Q3 2021 in Review

BBVA USA reduced its Abiomed Inc (ABMD) stake by 13% in Q3 2021, selling an estimated $65.4K and leaving 1,237 shares worth $403K. The position accounts for 0.02% of the portfolio, ranked #357.

BBVA USA first reported a position in ABMD in Q2 2021 and has held it in 2 quarters since. The position peaked at $446K in Q2 2021. 498 funds tracked by Wall St. Rank hold ABMD as of Q3 2021.

  • BBVA USA held 1,237 shares of Abiomed Inc worth $403K as of Q3 2021.
  • BBVA USA sold 193 Abiomed Inc shares in Q3 2021, an estimated $65.4K.
  • Abiomed Inc made up 0.02% of BBVA USA's portfolio in Q3 2021, its #357 holding.
  • BBVA USA first reported a position in Abiomed Inc in Q2 2021 and has held it in 2 quarters since.
  • BBVA USA's Abiomed Inc position peaked at $446K in Q2 2021.
  • 498 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.